Successful treatment of progressive macular hypomelanosis
https://doi.org/10.4081/dr.2020.8509
Submitted: 26 February 2020
Accepted: 14 July 2020
Published: 22 October 2020
Accepted: 14 July 2020
Abstract Views: 3941
PDF: 741
HTML: 891
HTML: 891
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Progressive Macular Hypomelanosis (PMH) is a common but often misdiagnosed disorder of acquired hypopigmentation. An adolescent female presented with irregular, hypopigmented patches ultimately diagnosed as PMH. Complete repigmentation was achieved with narrowband UVB phototherapy, benzoyl peroxide wash, and clindamycin lotion.
1. Relyveld GN, Menke HE, Westerhof W. Progressive macular hypomelanosis. Am J Clin Dermatol 2007;8:13–9.
https://www.ncbi.nlm.nih.gov/pubmed/17298102
2. Wang K, Nassef Y, Sahu J, et al. Facial involvement in progressive macular hypomelanosis. Cutis 2018;101:297–300.
https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/Document/April-2018/CT101004297.PDF
3. Shen LY, Kenner-Bell BM, Ricketts J, Kundu RV. Ethnic skin: kids are not just little people. Clin Dermatol 2016;34:690–7.
https://www-sciencedirect-com.ezproxy.umassmed.edu/science/article/pii/S0738081X16301808
4. Petersen RLW, Scholz CFP, Jensen A, et al. Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis. Eur J Microbiol Immunol 2017;7:37–45.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372479/
5. Pflederer RT, Wuennenberg JP, Foote C, et al. Use of woods lamp to diagnose progressive macular hypomelanosis. J Am Acad Dermatol 2017;77:e99–e100.
https://www-sciencedirect-com.ezproxy.umassmed.edu/science/article/pii/S0190962217316742
6. Relyveld GN, Kingswijk MM, Reitsma JB, et al. Benzoyl peroxide/clindamycin/uva is more effective than fluticasone/uva in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol 2006;55:836–43.
https://www.jaad.org/article/S0190-9622(06)00825-5/fulltext
7. Kim M-B, Kim G-W, Cho H-H, et al. Narrowband uvb treatment of progressive macular hypomelanosis. J Am Acad Dermatol 2012;66:598–605.
https://www.jaad.org/article/S0190-9622(11)00478-6/fulltext
8. Thng SG, Long VH, Chuah S, Tan VD. Efficacy and relapse rates of different treatment modalities for progressive macular hypomelanosis. Indian J Dermatol Venereol Leprol 2016;82:673.
http://www.ijdvl.com/article.asp?issn=0378-6323;year=2016;volume=82;issue=6;spage=673;epage=676;aulast=Thng
9. Sim J, Lee D, Lee J, Kim Y. Comparison of the clinical efficacy of nbuvb and nbuvb with benzoyl peroxide/clindamycin in progressive macular hypomelanosis. J Eur Acad Dermatol Venereol 2011;25:1318–23.
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1468-3083.2011.03980.x
https://www.ncbi.nlm.nih.gov/pubmed/17298102
2. Wang K, Nassef Y, Sahu J, et al. Facial involvement in progressive macular hypomelanosis. Cutis 2018;101:297–300.
https://mdedge-files-live.s3.us-east-2.amazonaws.com/files/s3fs-public/Document/April-2018/CT101004297.PDF
3. Shen LY, Kenner-Bell BM, Ricketts J, Kundu RV. Ethnic skin: kids are not just little people. Clin Dermatol 2016;34:690–7.
https://www-sciencedirect-com.ezproxy.umassmed.edu/science/article/pii/S0738081X16301808
4. Petersen RLW, Scholz CFP, Jensen A, et al. Propionibacterium acnes phylogenetic type III is associated with progressive macular hypomelanosis. Eur J Microbiol Immunol 2017;7:37–45.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372479/
5. Pflederer RT, Wuennenberg JP, Foote C, et al. Use of woods lamp to diagnose progressive macular hypomelanosis. J Am Acad Dermatol 2017;77:e99–e100.
https://www-sciencedirect-com.ezproxy.umassmed.edu/science/article/pii/S0190962217316742
6. Relyveld GN, Kingswijk MM, Reitsma JB, et al. Benzoyl peroxide/clindamycin/uva is more effective than fluticasone/uva in progressive macular hypomelanosis: a randomized study. J Am Acad Dermatol 2006;55:836–43.
https://www.jaad.org/article/S0190-9622(06)00825-5/fulltext
7. Kim M-B, Kim G-W, Cho H-H, et al. Narrowband uvb treatment of progressive macular hypomelanosis. J Am Acad Dermatol 2012;66:598–605.
https://www.jaad.org/article/S0190-9622(11)00478-6/fulltext
8. Thng SG, Long VH, Chuah S, Tan VD. Efficacy and relapse rates of different treatment modalities for progressive macular hypomelanosis. Indian J Dermatol Venereol Leprol 2016;82:673.
http://www.ijdvl.com/article.asp?issn=0378-6323;year=2016;volume=82;issue=6;spage=673;epage=676;aulast=Thng
9. Sim J, Lee D, Lee J, Kim Y. Comparison of the clinical efficacy of nbuvb and nbuvb with benzoyl peroxide/clindamycin in progressive macular hypomelanosis. J Eur Acad Dermatol Venereol 2011;25:1318–23.
https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1468-3083.2011.03980.x
Leonard, N., Krueger, S., & Rashighi, M. (2020). Successful treatment of progressive macular hypomelanosis. Dermatology Reports, 12(2). https://doi.org/10.4081/dr.2020.8509
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Downloads
Download data is not yet available.
Citations
